Along with implant location and size, incision location is an important variable that influences the final result of breast augmentation. The transareolar approach is not popular because of reported lactational difficulties, higher rates of capsular contracture, visibility of scars, and potential changes in nipple sensation. We describe a geometric zigzag transareolar incision for breast augmentation that can achieve imperceptible scarring. We believe that in selected patients the transareolar zigzag incision has its place among the different approaches used in breast augmentation today.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00266-008-9145-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically 'cold' tumor models.
Front Immunol
January 2025
Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Introduction: Hyperthermia is an established adjunct in multimodal cancer treatments, with mechanisms including cell death, immune modulation, and vascular changes. Traditional hyperthermia applications are resource-intensive and often associated with patient morbidity, limiting their clinical accessibility. Gold nanorods (GNRs) offer a precise, minimally invasive alternative by leveraging near-infrared (NIR) light to deliver targeted hyperthermia therapy (THT).
View Article and Find Full Text PDFAnchoring Ru single-atoms on MXene achieves dual-enzyme activities for mild photothermal augmented nanocatalytic therapy.
Nanoscale
January 2025
Key Laboratory of Superlight Materials and Surface Technology, Ministry of Education, College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, 150001, P. R. China.
Single-atom catalysts with abnormally high catalytic activity have garnered extensive attention and interest for their application in tumor therapy. Despite the advancements made with current nanotherapeutic agents, developing efficient systems for cancer treatment remains challenging due to low activity, uncontrollable behavior, and nonselective interactions. Herein, we have constructed Ru single-atom-anchored MXene nanozymes (Ru-TiCT-PEG) with a mild photothermal effect and multi-enzyme catalytic activity for synergistic tumor therapy.
View Article and Find Full Text PDFInvasive Lobular Carcinoma (ILC), a distinct subtype of breast cancer is hallmarked by E-Cadherin loss, slow proliferation, and strong hormone receptor positivity. ILC faces significant challenges in clinical management due to advanced stage at diagnosis, late recurrence, and development of resistance to endocrine therapy - a cornerstone of ILC treatment. To elucidate the mechanisms underlying endocrine resistance in ILC, ILC cell lines (MDA-MB-134-VI, SUM44PE) were generated to be resistant to tamoxifen, a selective estrogen receptor modulator.
View Article and Find Full Text PDFFibromatosis of the breast: a case report and literature review.
AME Case Rep
December 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Fibromatosis of the breast, also known as desmoid-type fibromatosis (DTF), is a rare tumor marked by the development of non-metastatic, locally aggressive tumors in breast tissue. It represents only 0.2% of all breast tumors.
View Article and Find Full Text PDFLiposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.
Pharmaceutics
December 2024
Department of Experimental Therapeutics, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Preclinical studies have shown that the anti-malarial drug hydroxychloroquine (HCQ) improves the anti-cancer effects of various therapeutic agents by impairing autophagy. These findings are difficult to translate in vivo as reaching an effective HCQ concentration at the tumor site for extended times is challenging. Previously, we found that free HCQ in combination with gefitinib (Iressa, ZD1839) significantly reduced tumor volume in immunocompromised mice bearing gefitinib-resistant JIMT-1 breast cancer xenografts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!